

PUBLICATIONS

1. **Vaux, DL**, BL Pike, and GJ Nossal, Antibody production by single, hapten-specific B lymphocytes: an antigen-driven cloning system free of filler or accessory cells. **Proc Natl Acad Sci U S A** (1981) 78: 7702-6.
2. Pike, BL, **DL Vaux**, I Clark-Lewis, JW Schrader, and GJ Nossal, Proliferation and differentiation of single hapten-specific B lymphocytes is promoted by T-cell factor(s) distinct from T-cell growth factor. **Proc Natl Acad Sci U S A** (1982) 79: 6350-4.
3. Pike, BL, **DL Vaux**, and GJ Nossal, Single cell studies on hapten-specific B lymphocytes: differential cloning efficiency of cells of various sizes. **J Immunol** (1983) 131: 554-60.
4. **Vaux, DL**, JM Adams, WS Alexander, and BL Pike, Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice. **J Immunol** (1987) 139: 3854-60.
5. **Vaux, DL**, S Cory, and JM Adams, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. **Nature** (1988) 335: 440-442.
6. Adams, JM, AW Harris, **DL Vaux**, WS Alexander, H Rosenbaum, SP Klincken, A Strasser, ML Bath, J McNeall, and S Cory, The transgenic window on lymphoid malignancy. **Princess Takamatsu Symp** (1989) 20: 297-309.
7. **Vaux, DL**, DNA fragmentation in cytolysis. **Immunol. Today** (1989) 10: 79.
8. **Vaux, DL**, *Follicular lymphoma*. Mechanisms of B-cell Neoplasia., ed. F.a.P. Melcher, M. 1989, Basel Switzerland.: Editiones Roche. 159-166.
9. Strasser, A, AW Harris, **DL Vaux**, E Webb, ML Bath, JM Adams, and S Cory, Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. **Curr Top Microbiol Immunol** (1990) 166: 175-181.
10. **Vaux, DL**, PA Lalor, S Cory, and GR Johnson, In vivo expression of interleukin 5 induces an eosinophilia and expanded Ly-1B lineage populations. **International Immunology** (1990) 2: 965-971.
11. Strasser, A, S Whittingham, **DL Vaux**, ML Bath, JM Adams, S Cory, and AW Harris, Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. **Proc Natl Acad Sci USA** (1991) 88: 8661-8665.
12. **Vaux, DL**, Rapid recovery of DNA from agarose gels. **Trends Genet** (1992) 8: 81.
13. **Vaux, DL**, HL Aguila, and IL Weissman, Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. **Int Immunol** (1992) 4: 821-824.
14. **Vaux, DL**, IL Weissman, and SK Kim, Prevention of programmed cell death in *Caenorhabditis elegans* by human bcl-2. **Science** (1992) 258: 1955-1957.
15. **Vaux, DL**, Toward an understanding of the molecular mechanisms of physiological cell death. **Proc Natl Acad Sci USA** (1993) 90: 786-789.
16. **Vaux, DL**, A boom time for necrobiology. **Current Biology** (1993) 3: 877-878.
17. **Vaux, DL** and IL Weissman, Neither macromolecular synthesis nor myc is required for cell death via the mechanism that can be controlled by Bcl-2. **Mol Cell Biol** (1993) 13: 7000-5.
18. Hacker, G and **DL Vaux**, Expression of candidate cell death genes in cell lines during apoptosis. **Biochemistry & Cell Biology** (1994) 72: 451-454.
19. Haecker, G and **DL Vaux**, Viral, worm and radical implications for apoptosis. **TIBS** (1994) 19: 99-100.

20. Hawkins, CJ and **DL Vaux**, Analysis of the role of bcl-2 in apoptosis. **Immunological Reviews** (1994) 142: 127-139.
21. Qian, F, **DL Vaux**, and IL Weissman, expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. **Cell** (1994) 77: 335-347.
22. Ragland, BD, LS Ashley, **DL Vaux**, and WA Petri, Jr., Entamoeba histolytica: target cells killed by trophozoites undergo DNA fragmentation which is not blocked by Bcl-2. **Exp Parasitol** (1994) 79: 460-7.
23. Ragland, BD, **DL Vaux**, and WA Petri, DNA fragmentation of target cells killed by *Entamoeba histolytica* has a pattern characteristic of apoptosis. **Clinical Research** (1994) 42: A120-120.
24. **Vaux, DL**, G Haecker, and A Strasser, An evolutionary perspective on apoptosis. **Cell** (1994) 76: 777-779.
25. Yin, D, S Kondo, J Takeuchi, T Morimura, and **DL Vaux**, bcl 2 gene prevents apoptosis in murine acth secreting adenoma cells induced by bromocriptine. **International Journal of Oncology** (1994) 4: 187-191.
26. Hacker, G and **DL Vaux**, The medical significance of physiological cell death. **Med Res Rev** (1995) 15: 299-311.
27. Hacker, G and **DL Vaux**, Apoptosis. A sticky business. **Curr Biol** (1995) 5: 622-4.
28. **Vaux, DL**, Apoptosis research. **Scientist** (1995) 9.
29. **Vaux, DL**, Immunology. Ways around rejection. **Nature** (1995) 377: 576-7.
30. **Vaux, DL** and G Hacker, Cloning of mouse RP-8 cDNA and its expression during apoptosis of lymphoid and myeloid cells. **DNA & Cell Biology** (1995) 14: 189-193.
31. **Vaux, DL** and G Hacker, Hypothesis: apoptosis caused by cytotoxins represents a defensive response that evolved to combat intracellular pathogens. **Clin Exp Pharmacol Physiol** (1995) 22: 861-3.
32. Hacker, G, CJ Hawkins, KG Smith, and **DL Vaux**, Effects of viral inhibitors of apoptosis in models of mammalian cell death. **Behring Inst Mitt** (1996) 97: 118-26.
33. Hawkins, CJ, AG Uren, G Hacker, RL Medcalf, and **DL Vaux**, Inhibition of interleukin 1 beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. **Proc Natl Acad Sci U S A** (1996) 93: 13786-90.
34. Smith, KGC, A Strasser, and **DL Vaux**, Crma expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. **EMBO J** (1996) 15: 5167-5176.
35. Uren, AG, M Pakusch, CJ Hawkins, KL Puls, and **DL Vaux**, Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. **Proc. Natl Acad. Sci. USA** (1996) 93: 4974-4978.
36. Uren, AG and **DL Vaux**, TRAF proteins and meprins share a conserved domain. **Trends in Biochemical Sciences** (1996) 21: 244-245.
37. Uren, AG and **DL Vaux**, Molecular and clinical aspects of apoptosis. **Pharmacology & Therapeutics** (1996) 72: 37-50.
38. **Vaux, DL** and A Strasser, The molecular biology of apoptosis. **Proc Natl Acad Sci USA** (1996) 93: 2239-2244.
39. **Vaux, DL**, D Whitney, and IL Weissman, Activation of physiological cell death mechanisms by a necrosis-causing agent. **Microscopy Research & Technique** (1996) 34:

259-266.

40. Allison, J, HM Georgiou, A Strasser, and **DL Vaux**, Transgenic expression of cd95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. **Proc Natl Acad Sci USA** (1997) 94: 3943-3947.
41. Ekert, PG and **DL Vaux**, Apoptosis, haemopoiesis and leukaemogenesis. **Baillieres Clinical Haematology** (1997) 10: 561-576.
42. Ekert, PG and **DL Vaux**, Apoptosis and the immune system. **British Medical Bulletin** (1997) 53: 591-603.
43. Hacker, G and **DL Vaux**, A chronology of cell death. **Apoptosis** (1997) 2: 247-256.
44. Hawkins, CJ and **DL Vaux**, The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. **Semin Immunol** (1997) 9: 25-33.
45. Irmeler, M, K Hofmann, **DL Vaux**, and J Tschopp, Direct physical interaction between the caenorhabditis elegans death proteins ced-3 and ced-4. **Febs Letters** (1997) 406: 189-190.
46. Strasser, A, DC Huang, and **DL Vaux**, The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. **Biochim Biophys Acta** (1997) 24: F151-78.
47. Strasser, A, DCS Huang, and **DL Vaux**, The significance of defects in cell death control for tumourigenesis and resistance to chemotherapy. **Biochim Biophys Acta** (1997).
48. Sutton, VR, **DL Vaux**, and JA Trapani, Bcl-2 prevents apoptosis induced by perforin and granzyme b, but not that mediated by whole cytotoxic lymphocytes. **Journal of Immunology** (1997) 158: 5783-5790.
49. Uren, AG and **DL Vaux**, Viral inhibitors of apoptosis. **Vitam Horm** (1997) 53: 175-93.
50. **Vaux, DL**, CED-4--the third horseman of apoptosis. **Cell** (1997) 90: 389-90.
51. **Vaux, DL**, CJ Hawkins, AG Uren, and PG Ekert, Motor neurone disease and the life of motor neurones. **Med J Aust** (1997) 166: 109.
52. **Vaux, DL**, S Wilhelm, and G Hacker, Requirements for proteolysis during apoptosis. **Molecular & Cellular Biology** (1997) 17: 6502-6507.
53. Hawkins, CJ, PG Ekert, AG Uren, SP Holmgreen, and **DL Vaux**, Anti-apoptotic potential of insect cellular anDL Viral iaps in mammalian cells. **Cell Death & Differentiation** (1998) 5: 569-576.
54. Silke, J and **DL Vaux**, Cell death: shadow boxing. **Curr Biol** (1998) 8: R528-31.
55. Uren, AG, EJ Coulson, and **DL Vaux**, Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. **Trends Biochem. Sci.** (1998) 23: 159-162.
56. **Vaux, DL**, Immunopathology of apoptosis - introduction and overview. **Springer Seminars in Immunopathology** (1998) 19: 271-278.
57. **Vaux, DL**, Immunology - ways around rejection (retraction of vol 377, pg 576, 1995). **Nature** (1998) 394: 133.
58. **Vaux, DL**, Immunopathology of apoptosis--introduction and overview. **Springer Semin Immunopathol** (1998) 19: 271-8.
59. Cory, S, **DL Vaux**, A Strasser, AW Harris, and JM Adams, Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. **Cancer Research** (1999) 59: 1685S-1692S.
60. Day, CL, C Dupont, M Lackmann, **DL Vaux**, and MG Hinds, Solution structure and mutagenesis of the caspase recruitment domain (CARD) from Apaf-1. **Cell Death &**

Differentiation (1999) 6: 1125-1132.

61. Ekert, PG, J Silke, and **DL Vaux**, Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors. **EMBO Journal** (1999) 18: 330-338.
62. Ekert, PG, J Silke, and **DL Vaux**, Caspase inhibitors. **Cell Death & Differentiation** (1999) 6: 1081-1086.
63. Hinds, MG, RS Norton, **DL Vaux**, and CL Day, Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. **Nature Structural Biology** (1999) 6: 648-651.
64. Magnusson, C and **DL Vaux**, Signalling by CD95 and TNF receptors: Not only life and death. **Immunology & Cell Biology** (1999) 77: 41-46.
65. Montaner, LJ, RP da Silva, J Sun, S Sutterwala, M Hollinshead, **DL Vaux**, and S Gordon, Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-gamma or IL-10. **J Immunol** (1999) 162: 4606-13.
66. Uren, AG, T Beilharz, MJ O'Connell, SJ Bugg, R van Driel, **DL Vaux**, and T Lithgow, Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. . **Proc Natl Acad Sci USA** (1999) 96: 10170-10175.
67. **Vaux, DL**, Caspases and apoptosis - biology and terminology. **Cell Death & Differentiation** (1999) 6: 493-494.
68. **Vaux, DL** and SJ Korsmeyer, Cell death in development. **Cell** (1999) 96: 245-254.
69. Verhagen, AM and **DL Vaux**, Molecular mechanisms of apoptosis: an overview. **Results Probl Cell Differ** (1999) 23: 11-24.
70. Silke, J, AM Verhagen, PG Ekert, and **DL Vaux**, Sequence as well as functional similarity for DIABLO/Smac and Grim, Reaper and Hid? **Cell Death & Differentiation** (2000) 7: 1275.
71. Speliotes, EK, AG Uren, **DL Vaux**, and HR Horvitz, The survivin-like *C. elegans* BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. **Mol Cell** (2000) 6: 211-223.
72. Strasser, A, K Newton, LA O'Reilly, M Pellegrini, L O'Connor, H Puthalakath, L Cullen, L Tai, L Coultas, DCS Huang, A Villunger, P Bouillet, ML Bath, **DL Vaux**, S Cory, JM Adams, and AW Harris, How, when, and why do lymphocytes die? **Immunologist** (2000) 8: 22-25.
73. Strasser, A and **DL Vaux**, Death in the snow: report on Keystone Conference on 'Apoptosis and Programmed Cell Death' at Breckenridge, CO, April 6-11th 1999. **Biochim Biophys Acta** (2000) 1470: R1-R11.
74. Uren, AG, L Wong, M Pakusch, KJ Fowler, FJ Burrows, **DL Vaux**, and KH Choo, Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. **Curr Biol** (2000) 10: 1319-28.
75. **Vaux, D**, Science down under. **Curr Biol** (2000) 10: R321.
76. **Vaux, DL** and RA Flavell, Apoptosis genes and autoimmunity. **Current Opinion in Immunology** (2000) 12: 719-724.
77. Verhagen, AM, PG Ekert, M Pakusch, J Silke, LM Connolly, GE Reid, RL Moritz, RJ Simpson, and **DL Vaux**, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. **Cell** (2000) 102: 43-53.
78. Ekert, PG, J Silke, CJ Hawkins, AM Verhagen, and **DL Vaux**, DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. **Journal of Cell Biology** (2001) 152: 483-490.

79. Silke, J, PG Ekert, CL Day, CJ Hawkins, M Baca, J Chew, M Pakusch, AM Verhagen, and **DL Vaux**, Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. **EMBO Journal** (2001) 20: 3114-3123.
80. Silke, J and **DL Vaux**, Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis. **Journal of Cell Science** (2001) 114: 1821-1827.
81. **Vaux, DL**, In support of errors. **Current Biology** (2001) 11: R288.
82. Verhagen, AM, EJ Coulson, and **DL Vaux**, Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. **Genome Biol** (2001) 2: REVIEWS3009.
83. Verhagen, AM, M Pakusch, J Silke, and **DL Vaux**, TNF and CD95 promote IL-8 gene transactivation via independent elements in colon carcinoma cells. **Cytokine** (2001) 15: 108-112.
84. Kumar, S and **DL Vaux**, A Cinderella caspase takes center stage. **Science** (2002) 297: 1290-1291.
85. Marsden, VS, L O'Connor, LA O'Reilly, J Silke, D Metcalf, PG Ekert, DC Huang, F Cecconi, K Kuida, KJ Tomaselli, S Roy, DW Nicholson, **DL Vaux**, P Bouillet, JM Adams, and A Strasser, Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. **Nature** (2002) 419: 634-7.
86. O'Reilly, LA, P Ekert, N Harvey, V Marsden, L Cullen, **DL Vaux**, G Hacker, C Magnusson, M Pakusch, F Cecconi, K Kuida, A Strasser, DC Huang, and S Kumar, Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. **Cell Death Differ** (2002) 9: 832-41.
87. Read, SH, BC Baliga, PG Ekert, **DL Vaux**, and S Kumar, A novel Apaf-1-independent putative caspase-2 activation complex. **Journal of Cell Biology** (2002) 159: 739-745.
88. Silke, J, CJ Hawkins, PG Ekert, J Chew, CL Day, M Pakusch, AM Verhagen, and **DL Vaux**, The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. **J Cell Biol** (2002) 157: 115-24.
89. Tikoo, A, L O'Reilly, CL Day, AM Verhagen, M Pakusch, and **DL Vaux**, Tissue distribution of Diablo/Smac revealed by monoclonal antibodies. **Cell Death & Differentiation** (2002) 9: 710-716.
90. **Vaux, DL**, The buzz about BAFF. **Journal of Clinical Investigation** (2002) 109: 17-18.
91. **Vaux, DL**, Apoptosis timeline. **Cell Death & Differentiation** (2002) 9: 349-354.
92. **Vaux, DL**, Apoptosis and toxicology--what relevance? **Toxicology** (2002) 181-182: 3-7.
93. Verhagen, AM, J Silke, PG Ekert, M Pakusch, H Kaufmann, LM Connolly, CL Day, A Tikoo, R Burke, C Wrobel, RL Moritz, RJ Simpson, and **DL Vaux**, HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. **J Biol Chem** (2002) 277: 445-454.
94. Verhagen, AM and **DL Vaux**, Cell death regulation by the mammalian IAP antagonist Diablo/Smac. **Apoptosis** (2002) 7: 163-166.
95. Kaufmann, SH and **DL Vaux**, Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. **Oncogene** (2003) 22: 7414-30.
96. **Vaux, DL** and J Silke, Mammalian mitochondrial IAP binding proteins. **Biochem Biophys Res Commun** (2003) 304: 499-504.
97. **Vaux, DL** and J Silke, HtrA2/Omi, a Sheep in Wolf's Clothing. **Cell** (2003) 115: 251-3.
98. Ekert, PG, SH Read, J Silke, VS Marsden, H Kaufmann, CJ Hawkins, R Gerl, S Kumar, and **DL Vaux**, Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether

- factor-deprived or drug-treated cells die. **J Cell Biol** (2004) 165: 835-42.
99. Gerl, R and **DL Vaux**, Apoptosis in the development and treatment of cancer. **Carcinogenesis** (2004) 16: 16.
 100. Marsden, VS, PG Ekert, M Van Delft, **DL Vaux**, JM Adams, and A Strasser, Bcl-2-regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase-9. **J Cell Biol** (2004) 165: 775-80.
 101. Silke, J, T Kratina, PG Ekert, M Pakusch, and **DL Vaux**, Unlike Diablo/smact, Grim promotes global ubiquitination and specific degradation of X chromosome-linked inhibitor of apoptosis (XIAP) and neither cause apoptosis. **J Biol Chem** (2004) 279: 4313-21.
 102. **Vaux, DL**, Early work on the function of Bcl-2, an interview with David **DL Vaux**. **Cell Death Differ** (2004) 11: 28-32.
 103. **Vaux, DL**, Error message. **Nature** (2004) 428: 799.
 104. Burri, L, Y Strahm, CJ Hawkins, IE Gentle, MA Puryer, A Verhagen, B Callus, **DL Vaux**, and T Lithgow, Mature DIABLO/Smac is produced by the IMP protease complex on the mitochondrial inner membrane. **Mol Biol Cell** (2005) 16: 2926-33.
 105. Ekert, PG and **DL Vaux**, The mitochondrial death squad: hardened killers or innocent bystanders? **Curr Opin Cell Biol** (2005) 17: 626-30.
 106. Gerl, R and **DL Vaux**, Apoptosis in the development and treatment of cancer. **Carcinogenesis** (2005) 26: 263-70.
 107. Kroemer, G, WS El-Deiry, P Golstein, ME Peter, **DL Vaux**, P Vandenabeele, B Zhivotovsky, MV Blagosklonny, W Malorni, RA Knight, M Piacentini, S Nagata, and G Melino, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. **Cell Death Differ** (2005) 2: 1463-7.
 108. Olayioye, MA, H Kaufmann, M Pakusch, **DL Vaux**, GJ Lindeman, and JE Visvader, XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. **Cell Death Differ** (2005) 12: 87-90.
 109. Silke, J, T Kratina, D Chu, PG Ekert, CL Day, M Pakusch, DC Huang, and **DL Vaux**, Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. **Proc Natl Acad Sci U S A** (2005) 102: 16182-7.
 110. **Vaux, DL** and J Silke, IAPs, RINGs and ubiquitylation. **Nat Rev Mol Cell Biol** (2005) 6: 287-97.
 111. **Vaux, DL** and J Silke, IAPs--the ubiquitin connection. **Cell Death Differ** (2005) 12: 1205-7.
 112. Callus, BA, AM Verhagen, and **DL Vaux**, Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. **Febs J** (2006) 273: 4264-76.
 113. Ekert, PG, AM Jabbour, A Manoharan, JE Heraud, J Yu, M Pakusch, EM Michalak, PN Kelly, B Callus, T Kiefer, A Verhagen, J Silke, A Strasser, C Borner, and **DL Vaux**, Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma. **Blood** (2006) 108: 1461-8.
 114. Jabbour, AM, MA Puryer, JY Yu, T Lithgow, CD Riffkin, DM Ashley, **DL Vaux**, PG Ekert, and CJ Hawkins, Human Bcl-2 cannot directly inhibit the *Caenorhabditis elegans* Apaf-1 homologue CED-4, but can interact with EGL-1. **J Cell Sci** (2006) 119: 2572-82.
 115. Callus, BA and **DL Vaux**, Caspase inhibitors: viral, cellular and chemical. **Cell Death Differ** (2007) 14: 73-8.
 116. Cumming, G, F **DL** er, and **DL Vaux**, Error bars in experimental biology. **J Cell Biol**

- (2007) 177: 7-11.
117. Verhagen, AM, TK Kratina, CJ Hawkins, J Silke, PG Ekert, and **DL Vaux**, Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. **Cell Death Differ** (2007) 14: 348-57.
 118. Vince, JE, WW Wong, N Khan, R Feltham, D Chau, AU Ahmed, CA Benetatos, SK Chunduru, SM Condon, M McKinlay, R Brink, M Leverkus, V Tergaonkar, P Schneider, BA Callus, F Koentgen, **DL Vaux**, and J Silke, IAP antagonists target cIAP1 to induce TNF α -dependent apoptosis. **Cell** (2007) 131: 682-93.
 119. Callus, BA, PG Ekert, JE Heraud, AM Jabbour, A Kotevski, JE Vince, J Silke, and **DL Vaux**, Cytoplasmic p53 is not required for PUMA-induced apoptosis. **Cell Death Differ** (2008) 15: 213-5.
 120. Callus, BA, DM Moujallad, J Silke, R Gerl, AM Jabbour, PG Ekert, and **DL Vaux**, Triggering of apoptosis by Puma is determined by the threshold set by prosurvival Bcl-2 family proteins. **J Mol Biol** (2008) 384: 313-23.
 121. Knight, RA and **DL Vaux**, A tumour suppressor function of caspase-8? **Cell Death Differ** (2008) 15: 1337-8.
 122. Linke, K, PD Mace, CA Smith, **DL Vaux**, J Silke, and CL Day, Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. **Cell Death Differ** (2008) 15: 841-8.
 123. Mace, PD, K Linke, R Feltham, FR Schumacher, CA Smith, **DL Vaux**, J Silke, and CL Day, Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. **J Biol Chem** (2008) 283: 31633-40.
 124. **Vaux, DL**, ABT-737, proving to be a great tool even before it is proven in the clinic. **Cell Death Differ** (2008) 15: 807-8.
 125. Vince, JE, D Chau, B Callus, WW Wong, CJ Hawkins, P Schneider, M McKinlay, CA Benetatos, SM Condon, SK Chunduru, G Yeoh, R Brink, **DL Vaux**, and J Silke, TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF α . **J Cell Biol** (2008) 182: 171-84.
 126. Ahmed, AU, M Moulin, F Coumailleau, WW Wong, M Miasari, H Carter, J Silke, M Cohen-Tannoudji, JE Vince, and **DL Vaux**, CARP2 deficiency does not alter induction of NF-kappaB by TNF α . **Curr Biol** (2009) 19: R17-9.
 127. Jabbour, AM, JE Heraud, CP Daunt, T Kaufmann, J Sandow, LA O'Reilly, BA Callus, A Lopez, A Strasser, **DL Vaux**, and PG Ekert, Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. **Cell Death Differ** (2009) 16: 555-63.
 128. Kotevski, A, WD Cook, **DL Vaux**, and BA Callus, Identification of an Xiap-like pseudogene on mouse chromosome 7. **PLoS One** (2009) 4: e8078.
 129. Vince, JE, D Pantaki, R Feltham, PD Mace, SM Cordier, AC Schmukle, AJ Davidson, BA Callus, WW Wong, IE Gentle, H Carter, EF Lee, H Walczak, CL Day, **DL Vaux**, and J Silke, TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf- κ b and to prevent tnf-induced apoptosis. **J Biol Chem** (2009) 284: 35906-15.
 130. Wong, WW, IE Gentle, U Nachbur, H Anderton, **DL Vaux**, and J Silke, RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. **Cell Death Differ** (2009).
 131. Feltham, R, M Moulin, JE Vince, PD Mace, WW Wong, H Anderton, CL Day, **DL Vaux**, and J Silke, Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. **J Biol Chem** (2010) 285:

17525-36.

132. Lazarou, M, D Stojanovski, AE Frazier, A Kotevski, G Dewson, WJ Craigen, RM Kluck, **DL Vaux**, and MT Ryan, Inhibition of Bak activation by VDAC2 is dependent on the Bak transmembrane anchor. **J Biol Chem** (2010) 285: 36876-36883.
133. Lluis, JM, U Nachbur, WD Cook, IE Gentle, D Moujalled, M Moulin, WW Wong, N Khan, D Chau, BA Callus, JE Vince, J Silke, and **DL Vaux**, TAK1 Is Required for Survival of Mouse Fibroblasts Treated with TRAIL, and Does So by NF-kappaB Dependent Induction of cFLIPL. **PLoS One** (2010) 5: e8620.
134. Mace, PD, C Smits, **DL Vaux**, J Silke, and CL Day, Asymmetric recruitment of cIAPs by TRAF2. **J Mol Biol** (2010) 400: 8-15.
135. Feltham, R, B Bettjeman, R Budhidarmo, PD Mace, S Shirley, SM Condon, SK Chunduru, MA McKinlay, **DL Vaux**, J Silke, and CL Day, Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. **J Biol Chem** (2011) 286: 17015-28.
136. Gardam, S, VM Turner, H Carter, S Limaye, A Basten, F Koentgen, **DL Vaux**, J Silke, and R Brink, Deletion of cIAP1 and cIAP2 in B Lymphocytes Constitutively Activates Cell Survival Pathways and Inactivates the Germinal Center Response. **Blood** (2011) 117: 4041-4051.
137. Gentle, IE, WW Wong, JM Evans, A Bankovacki, WD Cook, NR Khan, U Nachbur, J Rickard, H Anderton, M Moulin, JM Lluis, DM Moujalled, J Silke, and **DL Vaux**, In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. **J Biol Chem** (2011) 286: 13282-91.
138. Moujalled, DM, WD Cook, JM Lluis, NR Khan, AU Ahmed, BA Callus, and **DL Vaux**, In mouse embryonic fibroblasts, neither caspase-8 nor cellular FLICE-inhibitory protein (FLIP) is necessary for TNF to activate NF-kappaB, but caspase-8 is required for TNF to cause cell death, and induction of FLIP by NF-kappaB is required to prevent it. **Cell Death Differ** (2011) 2011: AOP.
139. **Vaux, DL**, Apoptogenic factors released from mitochondria. **Biochim Biophys Acta** (2011) 1813: 546-50.
140. **Vaux, DL**, Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer. **F1000 Biol Rep** (2011) 1: B1-79.
141. **Vaux, DL**, A biased comment on double-blind review. **Br J Dermatol** (2011) 165: 1365-2133.
142. **Vaux, DL**, Response to "The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory". DOI: 10.1002/bies.201100025. **Bioessays** (2011) 33: 660-1.
143. **Vaux, DL**, In defense of the somatic mutation theory of cancer. **Bioessays** (2011) 33: 341-3.
144. Moujalled, DM, WD Cook, JM Lluis, NR Khan, AU Ahmed, BA Callus, and **DL Vaux**, In mouse embryonic fibroblasts, neither caspase-8 nor cellular FLICE-inhibitory protein (FLIP) is necessary for TNF to activate NF-kappaB, but caspase-8 is required for TNF to cause cell death, and induction of FLIP by NF-kappaB is required to prevent it. **Cell Death Differ** (2012) 19: 808-15.
145. Moulin, M, H Anderton, AK Voss, T Thomas, WW Wong, A Bankovacki, R Feltham, D Chau, WD Cook, J Silke, and **DL Vaux**, IAPs limit activation of RIP kinases by TNF receptor 1 during development. **Embo J** (2012) 31: 1679-91.

146. **Vaux, DL**, Research methods: Know when your numbers are significant. **Nature** (2012) 492: 180-1.
147. **Vaux, DL**, F Fiddler, and G Cumming, Replicates and repeats--what is the difference and is it significant? A brief discussion of statistics and experimental design. **EMBO Rep** (2012) 13: 291-6.
148. **Vaux, DL**, Another twist in the on and off affair between cell suicide and inflammation. **Cell Death Differ**. (2013) 20:974-975.
149. Moujalled, DM, WD Cook, T Okamoto, J Murphy, KE Lawlor, JE Vince, and **DL Vaux**, TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. **Cell Death Dis** (2013) 2013: 201.
150. **Vaux, DL**, Another twist in the on and off affair between cell suicide and inflammation. **Cell Death Differ** (2013) 20: 974-975. doi: 910.1038/cdd.2013.1057.
151. Allam, R, KE Lawlor, EC Yu, AL Mildenhall, DM Moujalled, RS Lewis, F Ke, KD Mason, MJ White, KJ Stacey, A Strasser, LA O'Reilly, W Alexander, BT Kile, **DL Vaux**, and JE Vince, Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming. **EMBO Rep** (2014) 2.
152. Cook, WD, DM Moujalled, TJ Ralph, P Lock, SN Young, JM Murphy, and **DL Vaux**, RIPK1- and RIPK3-induced cell death mode is determined by target availability. **Cell Death Differ** (2014) 6: 70.
153. Lindqvist, LM, M Heinlein, DC Huang, and **DL Vaux**, Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. **Proc Natl Acad Sci U S A** (2014) 27: 201406425.
154. Lindqvist, LM, and **DL Vaux**, BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy. **Autophagy** (2014) 10: 1474-1475.
155. Moujalled, DM, WD Cook, JM Murphy, and **DL Vaux**, Necroptosis induced by RIPK3 requires MLKL but not Drp1. **Cell Death Dis** (2014) 5:e1086
156. Rickard, JA, JA O'Donnell, JM Evans, N Lalaoui, AR Poh, T Rogers, JE Vince, KE Lawlor, RL Ninnis, H Anderton, C Hall, SK Spall, TJ Pheese, HE Abud, LH Cengia, J Corbin, S Mifsud, L Di Rago, D Metcalf, M Ernst, G Dewson, AW Roberts, WS Alexander, JM Murphy, PG Ekert, SL Masters, **DL Vaux**, BA Croker, M Gerlic, and J Silke, RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis. **Cell** (2014) 157: 1175-1188
157. **Vaux, DL**, Basic Statistics in Cell Biology. **Annu Rev Cell Dev Biol** (2014): 2.
158. Wong, WW, JE Vince, N Lalaoui, KE Lawlor, D Chau, A Bankovacki, H Anderton, D Metcalf, L O'Reilly, PJ Jost, JM Murphy, WS Alexander, A Strasser, **DL Vaux**, and J Silke, cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. **Blood** (2014) 123: 2562-2572.